NCT03503643Completed
Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at University of California at Los Angeles (UCLA)
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This is a prospective data collection of men who are electing to undergo prostate hemi-gland cryoablation. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using hemi-gland cryoablation. UCLA patients undergoing hemi-gland cryoablation are a unique cohort compared to prior research because all patients at UCLA have had a pre-treatment multi-parametric MRI and Ultrasound fusion targeted biopsy; they will be followed in a similar fashion. This results in more precise assessment of a target region of cancer for ablation which may, in turn, result in improved clinical outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 354 (actual)
- First submitted
- 29 Mar 2018
- Start date
- 14 Sept 2017
- Primary completion date
- 30 Aug 2025
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT03503643
What you commit to
- Study type: Observational
- Participants enrolled: 354
- From 14 Sept 2017 to the primary completion date, 30 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Medical contraindication to follow-up multi-parametric magnetic resonance imaging (mpMRI) or prostate biopsy
- Patients unable to tolerate general or regional anesthesia.
Who the study is looking for
- Patient has undergone or has elected to undergo hemi-gland cryoablation at UCLA
- Low or intermediate risk prostate cancer (Gleason ≤ 7) or select high-risk patients (Gleason 8 prostate cancer).
- Prostate volume of ≤ 70 cc
- Ability to complete informed consent form
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California, Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.